Blog

Archive for the ‘bioengineering’ category: Page 179

Jul 28, 2017

Why the super-rich are ploughing billions into the booming ‘immortality industry’

Posted by in categories: bioengineering, biotech/medical, computing, life extension, mapping, neuroscience

Zoom

Imagine a world in which you’re 90 years old and nowhere near middle-aged. An app on your phone has hacked your DNA code, so you know exactly when to go to the doctor to receive gene therapy to prevent all the diseases you don’t yet have. A microchip in your skin sends out a signal if you’re at risk of developing a wrinkle — so you step out of the sun and hotfoot it to your dermatologist. Every evening you sync your brain-mapping device with The Cloud, so even if you were caught up in a fatal accident you’d still be able to cheat death — every detail of your life would simply be downloaded to one of the perfect silicon versions you’d had made of yourself, ensuring you last until at least your 1,000th birthday.

This may sound like science fiction but it could be your fate — provided you can afford it. If current research develops into medicine, in the London of the future the super-rich won’t simply be able to buy the best things in life, they’ll be able to buy life itself by transforming themselves into a bio-engineered super-race, capable of living, if not forever, then for vastly longer than the current UK life expectancy of 81 years.

The science of turning back the clock has never been more advanced. In Boston, a drug capable of reversing half a lifetime of ageing in mice is about to be tested on humans in a medical trial monitored by NASA. NMN is a compound found naturally in broccoli which boosts levels of NAD, a protein involved in energy production that depletes as we get older. Professor David Sinclair, who headed up the initial research at Australia’s University of New South Wales, doses himself with 500mg daily, and claims that he has already become more youthful. According to blood tests analysing the state of the 48-year-old’s cells, prior to taking the pills Sinclair was in the same physical shape as a 57-year-old, but now he’s ‘31.4’.

Continue reading “Why the super-rich are ploughing billions into the booming ‘immortality industry’” »

Jul 26, 2017

Living computers: RNA circuits transform cells into nanodevices

Posted by in categories: bioengineering, biological, computing

Zoom

The interdisciplinary nexus of biology and engineering, known as synthetic biology, is growing at a rapid pace, opening new vistas that could scarcely be imagined a short time ago.

Read more

Jul 26, 2017

DARPA reveal project to develop gene editing system

Posted by in categories: bioengineering, biotech/medical

DARPA’s Safe Genes program plans to invest $65 million in seven teams that will collect data and develop gene editing tools to support bio-innovation and combat bio-threats such as invasive species.

Read more

Jul 26, 2017

New Study Suggests Previous Concerns about CRISPR Safety are Questionable

Posted by in categories: bioengineering, biotech/medical, food, genetics, life extension

Zoom

Gene editing aims to make precise changes to the target DNA whilst avoiding altering other parts of the DNA. The objective of this is to remove undesirable genetic traits and introduce desirable changes in both plants and animals. For example, it could be used to make crops more drought resistant, prevent or cure inherited genetic disorders or even treat age-related diseases.

As some of you may recall, back in May a study was published which claimed that the groundbreaking gene editing technique CRISPR caused thousands of off target and potentially dangerous mutations[1]. The authors of the paper called for regulators to investigate the safety of the technique, a move that could potentially set back research years if not decades.

This publication has been widely blasted by the research community due to serious questions about the study design being raised. One of the problems with this original paper was that it involved only three mice, this is an extremely poor number to make the kind of conclusions the paper did. There have been calls for the paper to be withdrawn and critical responses to the study.

Read more

Jul 20, 2017

Building the Safe Genes Toolkit

Posted by in categories: bioengineering, biotech/medical, genetics, health, security

Zoom

DARPA created the Safe Genes program to gain a fundamental understanding of how gene editing technologies function; devise means to safely, responsibly, and predictably harness them for beneficial ends; and address potential health and security concerns related to their accidental or intentional misuse. Today, DARPA announced awards to seven teams that will pursue that mission, led by: The Broad Institute of MIT and Harvard; Harvard Medical School; Massachusetts General Hospital; Massachusetts Institute of Technology; North Carolina State University; University of California, Berkeley; and University of California, Riverside. DARPA plans to invest $65 million in Safe Genes over the next four years as these teams work to collect empirical data and develop a suite of versatile tools that can be applied independently or in combination to support bio-innovation and combat bio-threats.

Gene editing technologies have captured increasing attention from healthcare professionals, policymakers, and community leaders in recent years for their potential to selectively disable cancerous cells in the body, control populations of disease-spreading mosquitos, and defend native flora and fauna against invasive species, among other uses. The potential national security applications and implications of these technologies are equally profound, including protection of troops against infectious disease, mitigation of threats posed by irresponsible or nefarious use of biological technologies, and enhanced development of new resources derived from synthetic biology, such as novel chemicals, materials, and coatings with useful, unique properties.

Achieving such ambitious goals, however, will require more complete knowledge about how gene editors, and derivative technologies including gene drives, function at various physical and temporal scales under different environmental conditions, across multiple generations of an organism. In parallel, demonstrating the ability to precisely control gene edits, turning them on and off under certain conditions or even reversing their effects entirely, will be paramount to translation of these tools to practical applications. By establishing empirical foundations and removing lingering unknowns through laboratory-based demonstrations, the Safe Genes teams will work to substantially minimize the risks inherent in such powerful tools.

Read more

Jul 14, 2017

Synthetic Biology and the Future of Creation

Posted by in categories: bioengineering, biotech/medical, genetics

For decades, biologists have read and edited DNA, the code of life. Revolutionary developments are giving scientists the power to write it. Instead of tinkering with existing life forms, synthetic biologists may be on the verge of writing the DNA of a living organism from scratch. In the next decade, according to some, we may even see the first synthetic human genome. Join a distinguished group of synthetic biologists, geneticists and bioengineers who are edging closer to breathing life into matter.

Watch the full program here: https://youtu.be/rU_pfCtSWF4

Continue reading “Synthetic Biology and the Future of Creation” »

Jul 6, 2017

This Silicon Valley company wants to ‘make better humans’ through biohacking

Posted by in category: bioengineering

Zoom

Optimizing human output is the next wave in tech growth, according to Michael Brandt, co-founder of Nootrobox.

Read more

Jul 5, 2017

Revita Life Sciences Continues to Advance Multi-Modality Protocol in Attempt to Revive Brain Dead Subjects

Posted by in categories: bioengineering, biotech/medical, cryonics, futurism, genetics, health, life extension, neuroscience, posthumanism

Revita Life Sciences, (http://revitalife.co.in) a biotechnology company focused on translational regenerative therapeutic applications, has announced that it is continuing to advance their novel, multi-modality clinical intervention in the state of brain death in humans.

“We have proactively continued to advance our multi-modality protocol, as an extended treatment before extubation, in an attempt to reverse the state of brain death” said Mr.Pranjal Agrawal, CEO Revita Life Sciences. “This treatment approach has yielded some very encouraging initial outcome signs, ranging from minor observations on blood pressure changes with response to painful stimuli, to eye opening and finger movements, with corresponding transient to permanent reversal changes in EEG patterns.”

Continue reading “Revita Life Sciences Continues to Advance Multi-Modality Protocol in Attempt to Revive Brain Dead Subjects” »

Jun 29, 2017

Bioquark Inc. and Lakmus LLC Announce Research Collaboration to Study Novel Biopharmaceuticals for Healthy Longevity Enhancement

Posted by in categories: aging, bioengineering, biotech/medical, disruptive technology, DNA, genetics, health, life extension, posthumanism, science

Philadelphia, PA, USA / Moscow, Russia — Bioquark, Inc., (www.bioquark.com) a life sciences company focused on the development of novel bio-products for regeneration, disease reversion, and healthy aging, and Moscow based, Lakmus LLC, a diversified investment company with business interests in pharmacies, restaurants, and real estate, announced a multi-disciplinary research collaboration with the FSBI Zakusov Institute of Pharmacology, Russian Academy of Medical Sciences (http://www.academpharm.ru/), and the Pavlov Institute of Physiology of the Russian Academy of Sciences (http://www.infran.ru/), to jointly study the pharmacotherapeutic longevity enhancement properties of its combinatorial regenerative biologic candidates.

“We are very excited about this continued collaboration with Lakmus,” said Ira S. Pastor, CEO, Bioquark Inc. “The disciplined development of our combinatorial biologic candidates (Bioquantines) for healthy longevity enhancement, represents another important step in our continued evolution as a company focused on a broad range of therapeutic products and services in the regenerative healthcare space.”

Throughout the 20th century, natural products formed the basis for a majority of all pharmaceuticals, biologics, and consumer healthcare products used by patients around the globe, generating trillions of dollars of wealth. However, many scientists believe we have only touched the surface with what the natural world, and its range of organisms, which from a health and wellness perspective are much further advanced than human beings, has to teach us.

Continue reading “Bioquark Inc. and Lakmus LLC Announce Research Collaboration to Study Novel Biopharmaceuticals for Healthy Longevity Enhancement” »

Jun 26, 2017

Biologists Plan to Bring the Woolly Mammoth Back to Life by 2019

Posted by in category: bioengineering

Zoom

A team of researchers believe they could bring back the woolly mammoth from extinction within the next two years.

Read more